Westpac Banking Corp Bei Gene, Ltd. Transaction History

Westpac Banking Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$221.31 - $316.61 $770,380 - $1.1 Million	-3,481 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$120.61 - $148.29 $419,843 - $516,197	3,481 New	3,481 $426,000
Q1 2019 May 14, 2019	SELL	$122.82 - $151.83 $1.23 Million - $1.52 Million	-10,008 Closed	0 $0
Q4 2018 Feb 07, 2019	BUY	$107.01 - $175.15 $1.07 Million - $1.75 Million	10,008 New	10,008 $1.4 Million
Q4 2017 Jan 18, 2018	SELL	$79.6 - $114.73 $509,439 - $734,272	-6,400 Closed	0 $0
Q3 2017 Oct 30, 2017	BUY	$66.19 - $103.46 $423,616 - $662,144	6,400	6,400 $0

254

42.4M

135K

111K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Westpac Banking Corp, based on Form 13F filings with the SEC.

Stay updated on Westpac Banking Corp with notifications on news.